Investor Relations

Latest News

View All News

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Read Press Release

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Read Press Release
employees discussing with whiteboard

Recent Event

H.C. Wainwright 27th Annual Global Investment Conference

View All Events

Company Information

FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

View Executive Team
View Board of Directors

Latest Financial Results

Q2 2025

Quarter Ended Jun 30, 2025
Earnings Release
HTML PDF
10-Q
HTML PDF
XBRL
ZIP

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Report Links

IR Contacts

Company

FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598
T: 281-671-5150
info@fibrobiologics.com

Investor Relations

Russo Partners
Nic Johnson
T: 212-845-4242
fibrobiologicsIR@russopr.com

Transfer Agent

VStock Transfer LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436

Connect With Us